US5614492A
(en)
*
|
1986-05-05 |
1997-03-25 |
The General Hospital Corporation |
Insulinotropic hormone GLP-1 (7-36) and uses thereof
|
US7138486B2
(en)
|
1986-05-05 |
2006-11-21 |
The General Hospital Corporation |
Insulinotropic hormone derivatives and uses thereof
|
US6849708B1
(en)
|
1986-05-05 |
2005-02-01 |
The General Hospital Corporation |
Insulinotropic hormone and uses thereof
|
US6284727B1
(en)
|
1993-04-07 |
2001-09-04 |
Scios, Inc. |
Prolonged delivery of peptides
|
US5705483A
(en)
*
|
1993-12-09 |
1998-01-06 |
Eli Lilly And Company |
Glucagon-like insulinotropic peptides, compositions and methods
|
US20020006899A1
(en)
*
|
1998-10-06 |
2002-01-17 |
Pospisilik Andrew J. |
Use of dipeptidyl peptidase IV effectors for lowering blood pressure in mammals
|
US6956026B2
(en)
*
|
1997-01-07 |
2005-10-18 |
Amylin Pharmaceuticals, Inc. |
Use of exendins for the reduction of food intake
|
ATE417622T1
(de)
*
|
1996-08-08 |
2009-01-15 |
Amylin Pharmaceuticals Inc |
Regulation gastrointestinaler beweglichkeit
|
AU6586298A
(en)
*
|
1997-03-31 |
1998-10-22 |
Eli Lilly And Company |
Glucagon-like peptide-1 analogs
|
US5981488A
(en)
*
|
1997-03-31 |
1999-11-09 |
Eli Lillly And Company |
Glucagon-like peptide-1 analogs
|
US7157555B1
(en)
*
|
1997-08-08 |
2007-01-02 |
Amylin Pharmaceuticals, Inc. |
Exendin agonist compounds
|
AU757748B2
(en)
|
1997-11-14 |
2003-03-06 |
Amylin Pharmaceuticals, Inc. |
Novel exendin agonist compounds
|
US7220721B1
(en)
*
|
1997-11-14 |
2007-05-22 |
Amylin Pharmaceuticals, Inc. |
Exendin agonist peptides
|
JP2001525371A
(ja)
*
|
1997-12-05 |
2001-12-11 |
イーライ・リリー・アンド・カンパニー |
Glp−1製剤
|
US6380357B2
(en)
*
|
1997-12-16 |
2002-04-30 |
Eli Lilly And Company |
Glucagon-like peptide-1 crystals
|
FR2777283B1
(fr)
*
|
1998-04-10 |
2000-11-24 |
Adir |
Nouveaux composes peptidiques analogues du glucagon-peptide- 1 (7-37), leur procede de preparation et les compositions pharmaceutiques qui les contiennent
|
DE19823831A1
(de)
*
|
1998-05-28 |
1999-12-02 |
Probiodrug Ges Fuer Arzneim |
Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
|
DE19828113A1
(de)
*
|
1998-06-24 |
2000-01-05 |
Probiodrug Ges Fuer Arzneim |
Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
|
WO2000007617A1
(en)
*
|
1998-07-31 |
2000-02-17 |
Novo Nordisk A/S |
Use of glp-1 and analogues for preventing type ii diabetes
|
US6720407B1
(en)
*
|
1998-08-28 |
2004-04-13 |
Eli Lilly And Company |
Method for administering insulinotropic peptides
|
EP1666054A1
(en)
|
1998-08-28 |
2006-06-07 |
Eli Lilly & Company |
Method for administering insulinotropic peptides
|
BR9913857A
(pt)
|
1998-09-17 |
2001-06-12 |
Lilly Co Eli |
Formulações de proteìna
|
US20030176357A1
(en)
*
|
1998-10-06 |
2003-09-18 |
Pospisilik Andrew J. |
Dipeptidyl peptidase IV inhibitors and their uses for lowering blood pressure levels
|
US6284725B1
(en)
*
|
1998-10-08 |
2001-09-04 |
Bionebraska, Inc. |
Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
|
US7259136B2
(en)
*
|
1999-04-30 |
2007-08-21 |
Amylin Pharmaceuticals, Inc. |
Compositions and methods for treating peripheral vascular disease
|
CZ295044B6
(cs)
*
|
1998-12-07 |
2005-05-18 |
Societe De Conseils De Recherches Et D'application |
Analogy GLP-1, mající kyselinu aminoizomáselnou na pozicích 8 a 35, jejich použití a farmaceutické prostředky je obsahující
|
DK1137666T5
(da)
|
1998-12-07 |
2009-10-05 |
Univ Tulane |
GLP-1-analoger
|
EP1600162A1
(en)
*
|
1998-12-22 |
2005-11-30 |
Eli Lilly & Company |
Shelf-stable formulation of glucagon-like peptide-1
|
EP1140148B1
(en)
*
|
1998-12-22 |
2005-10-26 |
Eli Lilly And Company |
Shelf-stable solution formulation of glucagon-like peptide-1
|
US20050272652A1
(en)
|
1999-03-29 |
2005-12-08 |
Gault Victor A |
Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
|
US6605648B1
(en)
*
|
1999-04-06 |
2003-08-12 |
Phillips Plastics Corporation |
Sinterable structures and method
|
US20090175821A1
(en)
*
|
1999-05-17 |
2009-07-09 |
Bridon Dominique P |
Modified therapeutic peptides with extended half-lives in vivo
|
US6514500B1
(en)
*
|
1999-10-15 |
2003-02-04 |
Conjuchem, Inc. |
Long lasting synthetic glucagon like peptide {GLP-!}
|
BR0010750A
(pt)
|
1999-05-17 |
2002-02-26 |
Conjuchem Inc |
Peptìdeos insulinotrópicos de longa duração
|
ES2291210T3
(es)
|
1999-06-21 |
2008-03-01 |
Eli Lilly And Company |
Uso sinergistico de tiazolidindionas con peptido-1 tipo glucagona y sus agonistas para tratar la diabetes no insulina-dependiente.
|
US6864234B1
(en)
|
1999-06-25 |
2005-03-08 |
Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. |
Somatostatin agonists
|
US9006175B2
(en)
*
|
1999-06-29 |
2015-04-14 |
Mannkind Corporation |
Potentiation of glucose elimination
|
EP2280020B1
(en)
|
1999-06-29 |
2016-02-17 |
MannKind Corporation |
Pharmaceutical formulations comprising a peptide complexed with a diketopiperazine
|
DE19940130A1
(de)
*
|
1999-08-24 |
2001-03-01 |
Probiodrug Ges Fuer Arzneim |
Neue Effektoren der Dipeptidyl Peptidase IV zur topischen Anwendung
|
DK1741447T3
(da)
|
2000-01-21 |
2013-12-09 |
Novartis Ag |
Kombinationer omfattende dipeptidylpeptidase-IV-inhibitorer og antidiabetiske midler
|
US6448045B1
(en)
*
|
2000-03-10 |
2002-09-10 |
The Regents Of The University Of California |
Inducing insulin gene expression in pancreas cells expressing recombinant PDX-1
|
PT2055302E
(pt)
*
|
2000-03-31 |
2014-12-03 |
Royalty Pharma Collection Trust |
Processo para a melhoria da sinalização de ilhéus em diabetes mellitus e para a sua prevenção
|
PT1294757E
(pt)
*
|
2000-06-16 |
2007-02-28 |
Lilly Co Eli |
Análogos do peptídeo-1 do tipo glucagon
|
KR100407792B1
(ko)
*
|
2000-08-02 |
2003-12-01 |
한국생명공학연구원 |
인간 글루카곤 유사펩타이드를 융합파트너로 이용한재조합 단백질의 제조방법
|
AR033390A1
(es)
|
2000-08-22 |
2003-12-17 |
Novartis Ag |
Una composicion farmaceutica que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina, el uso de dicha composicion para la fabricacion de un medicamento y un kit de partes
|
DK1322158T3
(da)
*
|
2000-10-02 |
2012-11-19 |
Usv Ltd |
Farmaceutiske præparater med langvarig frigivelse, som indeholder metformin, og fremgangsmåde til fremstilling deraf
|
IL155116A0
(en)
*
|
2000-10-27 |
2003-10-31 |
Probiodrug Ag |
Pharmaceutical compositions containing as inhibitor of dipeptidyl peptidase iv and of similar enzymes
|
WO2002043709A1
(fr)
|
2000-12-01 |
2002-06-06 |
Takeda Chemical Industries, Ltd. |
Procede de production d'une preparation contenant une substance bioactive
|
EP1351984A2
(en)
*
|
2000-12-13 |
2003-10-15 |
Eli Lilly And Company |
Amidated glucagon-like peptide-1
|
US7259233B2
(en)
*
|
2000-12-13 |
2007-08-21 |
Eli Lilly And Company |
Chronic treatment regimen using glucagon-like insulinotropic peptides
|
WO2002072146A2
(en)
*
|
2001-03-12 |
2002-09-19 |
Novartis Ag |
Combination of nateglinide or repaglinide with at least one further antidiabetic compound
|
US6573237B2
(en)
|
2001-03-16 |
2003-06-03 |
Eli Lilly And Company |
Protein formulations
|
US7368421B2
(en)
*
|
2001-06-27 |
2008-05-06 |
Probiodrug Ag |
Use of dipeptidyl peptidase IV inhibitors in the treatment of multiple sclerosis
|
US20030130199A1
(en)
*
|
2001-06-27 |
2003-07-10 |
Von Hoersten Stephan |
Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents
|
AU2002316811A1
(en)
*
|
2001-06-28 |
2003-03-03 |
Novo Nordisk A/S |
Stable formulation of modified glp-1
|
UA74912C2
(en)
*
|
2001-07-06 |
2006-02-15 |
Merck & Co Inc |
Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
|
US6642003B2
(en)
|
2001-08-02 |
2003-11-04 |
Cedars-Sinai Medical Center |
Human glucose-dependent insulin-secreting cell line
|
US20040214762A1
(en)
*
|
2001-08-16 |
2004-10-28 |
Hans-Ulrich Demuth |
Use of inhibitors of proline endopeptidase to modulate inositol (1,4,5) triphosphate concentration dependent on intracellular signal cascades
|
JP2005508895A
(ja)
*
|
2001-08-28 |
2005-04-07 |
イーライ・リリー・アンド・カンパニー |
Glp−1および基礎インスリンの予備混合物
|
US6844316B2
(en)
*
|
2001-09-06 |
2005-01-18 |
Probiodrug Ag |
Inhibitors of dipeptidyl peptidase I
|
US6911324B2
(en)
|
2001-10-18 |
2005-06-28 |
The Regents Of The University Of California |
Induction of beta cell differentiation in human cells
|
CA2463803A1
(en)
*
|
2001-10-19 |
2003-05-01 |
Eli Lilly And Company |
Biphasic mixtures of glp-1 and insulin
|
US7332819B2
(en)
*
|
2002-01-09 |
2008-02-19 |
Micron Technology, Inc. |
Stacked die in die BGA package
|
WO2003060071A2
(en)
|
2001-12-21 |
2003-07-24 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
EP1463752A4
(en)
*
|
2001-12-21 |
2005-07-13 |
Human Genome Sciences Inc |
ALBUMIN FUSION PROTEINS
|
US7105489B2
(en)
*
|
2002-01-22 |
2006-09-12 |
Amylin Pharmaceuticals, Inc. |
Methods and compositions for treating polycystic ovary syndrome
|
WO2003072195A2
(en)
|
2002-02-20 |
2003-09-04 |
Eli Lilly And Company |
Method for administering glp-1 molecules
|
US7141240B2
(en)
*
|
2002-03-12 |
2006-11-28 |
Cedars-Sinai Medical Center |
Glucose-dependent insulin-secreting cells transfected with a nucleotide sequence encoding GLP-1
|
ATE385193T1
(de)
|
2002-03-20 |
2008-02-15 |
Mannkind Corp |
Inhalationsgerät
|
US20030232761A1
(en)
*
|
2002-03-28 |
2003-12-18 |
Hinke Simon A. |
Novel analogues of glucose-dependent insulinotropic polypeptide
|
US20030191056A1
(en)
|
2002-04-04 |
2003-10-09 |
Kenneth Walker |
Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
|
MXPA04012497A
(es)
|
2002-07-04 |
2005-07-14 |
Zealand Pharma As |
Glp-1 y metodos para tratar la diabetes.
|
US20080260838A1
(en)
*
|
2003-08-01 |
2008-10-23 |
Mannkind Corporation |
Glucagon-like peptide 1 (glp-1) pharmaceutical formulations
|
US20040058876A1
(en)
*
|
2002-09-18 |
2004-03-25 |
Torsten Hoffmann |
Secondary binding site of dipeptidyl peptidase IV (DP IV)
|
WO2004031374A2
(en)
*
|
2002-09-18 |
2004-04-15 |
Prosidion Ltd. |
Secondary binding site of dipeptidyl peptidase iv (dp iv)
|
US7067488B2
(en)
|
2002-09-25 |
2006-06-27 |
Theratechnologies Inc. |
Modified GLP-1 peptides with increased biological potency
|
MXPA05003335A
(es)
*
|
2002-10-02 |
2005-07-05 |
Zealand Pharma As |
Compuestos de exendina-4 estabilizados.
|
EP1569680B1
(en)
*
|
2002-10-22 |
2009-01-21 |
Waratah Pharmaceuticals, Inc. |
Treatment of diabetes
|
US20040209803A1
(en)
*
|
2002-12-19 |
2004-10-21 |
Alain Baron |
Compositions for the treatment and prevention of nephropathy
|
US7790681B2
(en)
*
|
2002-12-17 |
2010-09-07 |
Amylin Pharmaceuticals, Inc. |
Treatment of cardiac arrhythmias with GLP-1 receptor ligands
|
JP2006514990A
(ja)
*
|
2002-12-27 |
2006-05-18 |
ディオベックス, インコーポレイテッド |
インスリン誘発性低血糖の予防および制御のための組成物および方法
|
US7655618B2
(en)
|
2002-12-27 |
2010-02-02 |
Diobex, Inc. |
Compositions and methods for the prevention and control of insulin-induced hypoglycemia
|
DE602004025205D1
(de)
*
|
2003-02-19 |
2010-03-11 |
Ipsen Pharma |
Glp-1-analoga
|
EP1605897B1
(en)
*
|
2003-03-19 |
2012-07-25 |
Eli Lilly And Company |
Polyethelene glycol link glp-1 compounds
|
DK1633440T3
(da)
*
|
2003-04-15 |
2008-09-08 |
Opperbas Holding Bv |
Farmaceutisk sammensætning omfattende proteiner og/eller polypeptider og kolloidale partikler
|
EP1620091B1
(en)
*
|
2003-05-05 |
2010-03-31 |
Probiodrug AG |
Inhibitors of glutaminyl cyclase
|
KR20120035203A
(ko)
*
|
2003-05-05 |
2012-04-13 |
프로비오드룩 아게 |
글루타미닐 및 글루타메이트 사이클라제의 이펙터의 용도
|
ES2425221T3
(es)
|
2003-05-30 |
2013-10-14 |
Amylin Pharmaceuticals, Llc |
Nuevos métodos y composiciones para suministro por vía transmucosa potenciado de péptidos y proteínas
|
JP4936884B2
(ja)
*
|
2003-06-03 |
2012-05-23 |
ノボ・ノルデイスク・エー/エス |
安定化された薬学的ペプチド組成物
|
CN1812808B
(zh)
*
|
2003-06-03 |
2012-07-04 |
诺沃挪第克公司 |
稳定化的药物肽组合物
|
PL1633391T3
(pl)
*
|
2003-06-03 |
2012-03-30 |
Novo Nordisk As |
Stabilizowane farmaceutycznie kompozycje peptydowe
|
NZ546322A
(en)
*
|
2003-10-15 |
2008-11-28 |
Probiodrug Ag |
Use of effectors of glutaminyl and glutamate cyclases
|
PL1687019T3
(pl)
*
|
2003-11-20 |
2018-05-30 |
Novo Nordisk A/S |
Formulacje peptydowe zawierające glikol propylenowy, które są optymalne do produkcji i do zastosowania w urządzeniach do wstrzykiwań
|
US7897566B2
(en)
|
2003-12-16 |
2011-03-01 |
Ipsen Pharma S.A.S. |
Analogues of GLP-1
|
JP2007514752A
(ja)
*
|
2003-12-16 |
2007-06-07 |
ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス |
Glp−1医薬組成物
|
US20060286129A1
(en)
*
|
2003-12-19 |
2006-12-21 |
Emisphere Technologies, Inc. |
Oral GLP-1 formulations
|
EP1711532A4
(en)
*
|
2004-01-30 |
2009-09-16 |
Waratah Pharmaceuticals Inc |
USE OF A GLP-1 AGONIST WITH GASTRINIC COMPOUNDS
|
WO2005075436A2
(en)
|
2004-02-05 |
2005-08-18 |
Probiodrug Ag |
Novel inhibitors of glutaminyl cyclase
|
PL1729795T3
(pl)
*
|
2004-02-09 |
2016-08-31 |
Human Genome Sciences Inc |
Białka fuzyjne albuminy
|
EP2100904B1
(en)
|
2004-04-23 |
2010-07-07 |
ConjuChem Biotechnologies Inc. |
Solid phase for use in a method for the purification of albumin conjugates
|
US20090069226A1
(en)
*
|
2004-05-28 |
2009-03-12 |
Amylin Pharmaceuticals, Inc. |
Transmucosal delivery of peptides and proteins
|
CN101010305B
(zh)
|
2004-08-20 |
2010-08-11 |
曼金德公司 |
二酮哌嗪合成的催化反应
|
DK1791542T3
(en)
|
2004-08-23 |
2015-06-15 |
Mannkind Corp |
Diketopiperazinsalte for pharmaceutical delivery
|
PL1789434T3
(pl)
*
|
2004-08-31 |
2014-07-31 |
Novo Nordisk As |
Zastosowanie tris(hydroksymetylo)aminometanu do stabilizacji peptydów, polipeptydów i białek
|
DE102004043153B4
(de)
*
|
2004-09-03 |
2013-11-21 |
Philipps-Universität Marburg |
Erfindung betreffend GLP-1 und Exendin
|
MX2007005521A
(es)
*
|
2004-11-12 |
2007-05-18 |
Novo Nordisk As |
Formulaciones estables de peptidos insulinotropicos.
|
WO2006069779A1
(en)
*
|
2004-12-30 |
2006-07-06 |
F. Hoffmann-La Roche Ag |
Preparing of peptides with excellent solubility
|
WO2006069697A1
(en)
*
|
2004-12-30 |
2006-07-06 |
F. Hoffmann-La Roche Ag |
Colorimetrically assessing peptide characteristics
|
US8263545B2
(en)
|
2005-02-11 |
2012-09-11 |
Amylin Pharmaceuticals, Inc. |
GIP analog and hybrid polypeptides with selectable properties
|
SG159551A1
(en)
|
2005-02-11 |
2010-03-30 |
Amylin Pharmaceuticals Inc |
Gip analog and hybrid polypeptides with selectable properties
|
WO2006097535A2
(en)
*
|
2005-03-18 |
2006-09-21 |
Novo Nordisk A/S |
Peptide agonists of the glucagon family with secretin like activity
|
CA2611002A1
(en)
|
2005-06-07 |
2006-12-14 |
The Rockefeller University |
Stimulation of pancreatic .beta. cell proliferation
|
MX2008001468A
(es)
*
|
2005-06-30 |
2008-04-07 |
Sod Conseils Rech Applic |
Composiciones farmaceuticas del peptido similar al glucagon-1.
|
US20070004616A1
(en)
*
|
2005-06-30 |
2007-01-04 |
Roland Cherif-Cheikh |
GLP-1 pharmaceutical compositions
|
GT200600381A
(es)
|
2005-08-25 |
2007-03-28 |
|
Compuestos organicos
|
MX358592B
(es)
|
2005-09-14 |
2018-08-27 |
Mannkind Corp |
Método para formulación de fármaco basado en el aumento de la afinidad de superficies de micropartículas cristalinas hacia agentes activos.
|
ES2397289T3
(es)
|
2005-09-22 |
2013-03-06 |
Biocompatibles Uk Ltd. |
Polipéptidos de fusión de GLP-1 (péptido 1 de tipo glucagón) con resistencia a peptidasa incrementada
|
WO2007051987A1
(en)
*
|
2005-11-01 |
2007-05-10 |
Activotec Spp Limited |
Insulinotropic compounds and uses thereof
|
GB0522295D0
(en)
*
|
2005-11-01 |
2005-12-07 |
Activotec Spp Ltd |
Peptides and uses thereof
|
US8039432B2
(en)
*
|
2005-11-09 |
2011-10-18 |
Conjuchem, Llc |
Method of treatment of diabetes and/or obesity with reduced nausea side effect
|
CN100374462C
(zh)
*
|
2005-11-21 |
2008-03-12 |
大连帝恩生物工程有限公司 |
截短胰高血糖素样肽1(sGLP-1)、制法及其应用
|
ES2779992T3
(es)
|
2005-12-20 |
2020-08-21 |
Univ Duke |
Métodos y composiciones para suministrar agentes activos con propiedades farmacológicas potenciadas
|
US8841255B2
(en)
|
2005-12-20 |
2014-09-23 |
Duke University |
Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
|
US20130172274A1
(en)
|
2005-12-20 |
2013-07-04 |
Duke University |
Methods and compositions for delivering active agents with enhanced pharmacological properties
|
EP1976876A4
(en)
*
|
2005-12-22 |
2010-01-13 |
Conjuchem Biotechnologies Inc |
PROCESS FOR PRODUCING PREFORMED ALBUMIN CONJUGATES AND THERAPEUTIC AGENT
|
RU2403059C2
(ru)
|
2006-02-22 |
2010-11-10 |
Маннкайнд Корпорейшн |
Способ улучшения фармацевтических свойств микрочастиц, содержащих дикетопиперазин и активный агент
|
EP2574624A1
(en)
*
|
2006-04-20 |
2013-04-03 |
Amgen Inc. |
GLP-1 compounds
|
PL2035451T3
(pl)
*
|
2006-06-23 |
2010-08-31 |
Hoffmann La Roche |
Synteza peptydów insulinotropowych
|
TW200821386A
(en)
*
|
2006-07-18 |
2008-05-16 |
Centocor Inc |
Human GLP-1 mimetibodies, compositions, methods and uses
|
US8497240B2
(en)
|
2006-08-17 |
2013-07-30 |
Amylin Pharmaceuticals, Llc |
DPP-IV resistant GIP hybrid polypeptides with selectable properties
|
UY30820A1
(es)
*
|
2006-12-21 |
2008-07-03 |
Centocor Inc |
Uso de agonistas del receptor de glp-1 de accion prolongada para mejorar la sensibilidad a la insulina y los perfiles lipidicos
|
JP2008169195A
(ja)
|
2007-01-05 |
2008-07-24 |
Hanmi Pharmaceutical Co Ltd |
キャリア物質を用いたインスリン分泌ペプチド薬物結合体
|
GB2448895A
(en)
*
|
2007-05-01 |
2008-11-05 |
Activotec Spp Ltd |
GLP-1 like compounds and uses thereof
|
JP2010538049A
(ja)
|
2007-09-05 |
2010-12-09 |
ノボ・ノルデイスク・エー/エス |
切断型glp−1誘導体及びその治療的使用
|
CN101868476B
(zh)
|
2007-09-05 |
2015-02-25 |
诺沃-诺迪斯克有限公司 |
胰高血糖素样肽-1衍生物及其制药用途
|
US8785396B2
(en)
|
2007-10-24 |
2014-07-22 |
Mannkind Corporation |
Method and composition for treating migraines
|
ES2547529T3
(es)
*
|
2007-10-24 |
2015-10-07 |
Mannkind Corporation |
Formulación en polvo seco inhalable que comprende GLP-1 para usar en el tratamiento de la hiperglucemia y diabetes por administración pulmonar
|
WO2009055742A2
(en)
|
2007-10-24 |
2009-04-30 |
Mannkind Corporation |
Delivery of active agents
|
DK2205624T3
(da)
*
|
2007-10-27 |
2017-01-02 |
Corden Pharma Colorado Inc |
Insulinotropisk peptidsyntese under anvendelse af faststof- og opløsningsfasekombinationsteknikker
|
WO2009059278A1
(en)
*
|
2007-11-02 |
2009-05-07 |
Centocor, Inc. |
Semi-synthetic glp-1 peptide-fc fusion constructs, methods and uses
|
WO2009075859A2
(en)
*
|
2007-12-11 |
2009-06-18 |
Conjuchem Biotechnologies Inc. |
Formulation of insulinotropic peptide conjugates
|
US20100317057A1
(en)
|
2007-12-28 |
2010-12-16 |
Novo Nordisk A/S |
Semi-recombinant preparation of glp-1 analogues
|
KR101548092B1
(ko)
|
2008-06-13 |
2015-08-27 |
맨카인드 코포레이션 |
건조 분말 흡입기 및 약물 투여 시스템
|
US8485180B2
(en)
|
2008-06-13 |
2013-07-16 |
Mannkind Corporation |
Dry powder drug delivery system
|
ES2421385T3
(es)
|
2008-06-20 |
2013-09-02 |
Mannkind Corp |
Aparato interactivo y procedimiento para establecer el perfil, en tiempo real, de esfuerzos de inhalación
|
EP2926825A1
(en)
|
2008-06-27 |
2015-10-07 |
Duke University |
Therapeutic agents comprising elastin-like peptides
|
TWI532497B
(zh)
|
2008-08-11 |
2016-05-11 |
曼凱公司 |
超快起作用胰島素之用途
|
MX344293B
(es)
|
2008-10-17 |
2016-12-13 |
Sanofi Aventis Deutschland |
Combinacion de una insulina y un agonista de glp-1.
|
AU2009314200B2
(en)
*
|
2008-11-17 |
2011-11-17 |
Merck Sharp & Dohme Corp. |
Substituted bicyclic amines for the treatment of diabetes
|
US8314106B2
(en)
|
2008-12-29 |
2012-11-20 |
Mannkind Corporation |
Substituted diketopiperazine analogs for use as drug delivery agents
|
EP2676695A3
(en)
|
2009-03-11 |
2017-03-01 |
MannKind Corporation |
Apparatus, system and method for measuring resistance of an inhaler
|
DK2429995T3
(da)
|
2009-05-15 |
2014-04-22 |
Novartis Ag |
Arylpyridiner som aldosteronsyntaseinhibitorer
|
KR20120036850A
(ko)
|
2009-05-15 |
2012-04-18 |
노파르티스 아게 |
알도스테론 신타제 억제제로서의 벤족사졸론 유도체
|
MX2011012628A
(es)
|
2009-05-28 |
2011-12-14 |
Novartis Ag |
Derivados amino-propionicos sustituidos como inhibidores de neprilisina.
|
AR076706A1
(es)
|
2009-05-28 |
2011-06-29 |
Novartis Ag |
Derivados aminobutiricos sustituidos como inhibidores de neprilisina
|
WO2010144789A2
(en)
|
2009-06-12 |
2010-12-16 |
Mannkind Corporation |
Diketopiperazine microparticles with defined specific surface areas
|
CA2804755C
(en)
|
2009-08-14 |
2018-06-05 |
Phasebio Pharmaceuticals, Inc. |
Modified vasoactive intestinal peptides
|
JP5784622B2
(ja)
|
2009-11-03 |
2015-09-24 |
マンカインド コーポレ−ション |
吸入活動をシミュレートするための装置及び方法
|
KR101772372B1
(ko)
|
2009-11-13 |
2017-08-29 |
사노피-아벤티스 도이칠란트 게엠베하 |
Glp-1 효능제 및 메티오닌을 포함하는 약제학적 조성물
|
AU2010317995B2
(en)
|
2009-11-13 |
2014-04-17 |
Sanofi-Aventis Deutschland Gmbh |
Pharmaceutical composition comprising a GLP-1 agonist, an insulin, and methionine
|
EP2993169B1
(en)
|
2009-11-17 |
2017-12-20 |
Novartis AG |
Aryl-pyridine derivatives as aldosterone synthase inhibitors
|
JO2967B1
(en)
|
2009-11-20 |
2016-03-15 |
نوفارتس ايه جي |
Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
|
EP2507234B1
(en)
|
2009-11-30 |
2014-03-12 |
Novartis AG |
Imidazole derivatives as aldosterone synthase inhibitors
|
US9168288B2
(en)
|
2010-04-09 |
2015-10-27 |
Mount Sinai Hospital |
Methods for treating disorders of the gastrointestinal tract using a GLP-1 agonist
|
JP5969461B2
(ja)
|
2010-04-27 |
2016-08-17 |
ジーランド ファーマ アクティーゼルスカブ |
Glp−1受容体作動薬とガストリンとのペプチド複合体及びその使用
|
CA2802931C
(en)
|
2010-05-17 |
2016-10-04 |
Zhejiang Beta Pharma Inc. |
Novel glucagon like peptide analogs, composition, and method of use
|
CN102985125A
(zh)
|
2010-06-21 |
2013-03-20 |
曼金德公司 |
干粉药物输送***和方法
|
CN103179978A
(zh)
|
2010-08-30 |
2013-06-26 |
赛诺菲-安万特德国有限公司 |
Ave0010用于制造供治疗2型糖尿病用的药物的用途
|
US8673974B2
(en)
|
2010-11-16 |
2014-03-18 |
Novartis Ag |
Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
|
US8877815B2
(en)
|
2010-11-16 |
2014-11-04 |
Novartis Ag |
Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
|
RU2600440C3
(ru)
|
2010-12-16 |
2021-12-10 |
Ново Нордиск А/С |
Твердые композиции, содержащие агонист glp-1 и соль n-(8-(2-гидроксибензоил)амино)каприловой кислоты
|
CN103298456A
(zh)
*
|
2011-01-19 |
2013-09-11 |
诺沃—诺迪斯克有限公司 |
Glp-1颗粒和组合物
|
JP6133270B2
(ja)
|
2011-04-01 |
2017-05-24 |
マンカインド コーポレイション |
薬剤カートリッジのためのブリスター包装
|
WO2012140117A1
(en)
|
2011-04-12 |
2012-10-18 |
Novo Nordisk A/S |
Double-acylated glp-1 derivatives
|
US9821032B2
(en)
|
2011-05-13 |
2017-11-21 |
Sanofi-Aventis Deutschland Gmbh |
Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
|
CA2873553C
(en)
|
2011-06-06 |
2020-01-28 |
Phasebio Pharmaceuticals, Inc. |
Use of modified vasoactive intestinal peptides in the treatment of hypertension
|
WO2012174472A1
(en)
|
2011-06-17 |
2012-12-20 |
Mannkind Corporation |
High capacity diketopiperazine microparticles
|
AU2012300978B2
(en)
|
2011-08-29 |
2017-04-27 |
Sanofi-Aventis Deutschland Gmbh |
Pharmaceutical combination for use in glycemic control in diabetes type 2 patients
|
TWI559929B
(en)
|
2011-09-01 |
2016-12-01 |
Sanofi Aventis Deutschland |
Pharmaceutical composition for use in the treatment of a neurodegenerative disease
|
JP6018640B2
(ja)
|
2011-10-24 |
2016-11-02 |
マンカインド コーポレイション |
疼痛を緩和するのに有効な鎮痛組成物並びに当該組成物を含む乾燥粉末及び乾燥粉末薬剤輸送システム
|
AU2012331053A1
(en)
|
2011-11-03 |
2014-05-29 |
Zealand Pharma A/S |
GLP-1 receptor agonist peptide gastrin conjugates
|
CN104011064A
(zh)
|
2011-12-29 |
2014-08-27 |
诺沃—诺迪斯克有限公司 |
包含非成蛋白质性的氨基酸的二肽
|
ES2952874T3
(es)
|
2012-03-22 |
2023-11-06 |
Novo Nordisk As |
Composiciones de péptidos GLP-1 y preparación de estas
|
DK2827845T3
(en)
|
2012-03-22 |
2019-04-01 |
Novo Nordisk As |
COMPOSITIONS INCLUDING A PROCEDURE AND PREPARING THEREOF
|
CN104487056A
(zh)
|
2012-06-20 |
2015-04-01 |
诺和诺德A/S(股份有限公司) |
包含肽和递送剂的片剂制剂
|
US20150157619A1
(en)
|
2012-07-10 |
2015-06-11 |
Takeda Pharmaceutical Company Limited |
Pharmaceutical preparation for injection
|
RU2650035C2
(ru)
|
2012-07-12 |
2018-04-06 |
Маннкайнд Корпорейшн |
Системы и способы доставки сухих порошковых лекарств
|
CA2878991C
(en)
|
2012-07-23 |
2021-12-07 |
Zealand Pharma A/S |
Glucagon analogues
|
TWI608013B
(zh)
|
2012-09-17 |
2017-12-11 |
西蘭製藥公司 |
升糖素類似物
|
EP2911690A1
(en)
|
2012-10-26 |
2015-09-02 |
MannKind Corporation |
Inhalable influenza vaccine compositions and methods
|
UY35144A
(es)
|
2012-11-20 |
2014-06-30 |
Novartis Ag |
Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
|
TWI641381B
(zh)
|
2013-02-04 |
2018-11-21 |
法商賽諾菲公司 |
胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
|
KR20150119109A
(ko)
|
2013-02-14 |
2015-10-23 |
노파르티스 아게 |
Nep (중성 엔도펩티다제) 억제제로서의 치환된 비스페닐 부타노익 포스폰산 유도체
|
EP3587404B1
(en)
|
2013-03-15 |
2022-07-13 |
MannKind Corporation |
Microcrystalline diketopiperazine compositions, methods for preparation and use thereof
|
MX2020009878A
(es)
|
2013-07-18 |
2022-07-27 |
Mannkind Corp |
Composiciones farmaceuticas en polvo seco estables al calor y metodos.
|
TN2016000031A1
(en)
|
2013-07-25 |
2017-07-05 |
Novartis Ag |
Cyclic polypeptides for the treatment of heart failure
|
KR20160031552A
(ko)
|
2013-07-25 |
2016-03-22 |
노파르티스 아게 |
합성 아펠린 폴리펩티드의 생체접합체
|
EP3030294B1
(en)
|
2013-08-05 |
2020-10-07 |
MannKind Corporation |
Insufflation apparatus
|
US9988429B2
(en)
|
2013-10-17 |
2018-06-05 |
Zealand Pharma A/S |
Glucagon analogues
|
UA122767C2
(uk)
|
2013-10-17 |
2021-01-06 |
Зіленд Фарма А/С |
Ацильований аналог глюкагону
|
EA035688B1
(ru)
|
2013-11-06 |
2020-07-27 |
Зилэнд Фарма А/С |
Соединения, которые представляют собой тройные агонисты глюкагона, glp-1 и gip
|
TWI670281B
(zh)
|
2013-11-06 |
2019-09-01 |
西蘭製藥公司 |
Gip-glp-1雙重促效劑化合物及方法
|
MX2016008977A
(es)
|
2014-01-09 |
2016-10-04 |
Sanofi Sa |
Formulaciones farmaceuticas de insulina aspart estabilizadas.
|
AU2015205624A1
(en)
|
2014-01-09 |
2016-07-14 |
Sanofi |
Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
|
CA2932875A1
(en)
|
2014-01-09 |
2015-07-16 |
Sanofi |
Stabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives
|
US10307464B2
(en)
|
2014-03-28 |
2019-06-04 |
Mannkind Corporation |
Use of ultrarapid acting insulin
|
CA2947982C
(en)
|
2014-05-08 |
2022-11-29 |
Phasebio Pharmaceuticals, Inc. |
Methods and compositions for treating cystic fibrosis
|
US10561806B2
(en)
|
2014-10-02 |
2020-02-18 |
Mannkind Corporation |
Mouthpiece cover for an inhaler
|
WO2016066744A2
(en)
|
2014-10-29 |
2016-05-06 |
Zealand Pharma A/S |
Gip agonist compounds and methods
|
TN2017000235A1
(en)
|
2014-12-12 |
2018-10-19 |
Sanofi Aventis Deutschland |
Insulin glargine/lixisenatide fixed ratio formulation
|
CN105820233B
(zh)
*
|
2015-01-04 |
2021-06-15 |
甘李药业股份有限公司 |
一种胰岛素衍生物的制备方法
|
CU20170093A7
(es)
|
2015-01-23 |
2017-09-06 |
Novartis Ag |
Conjugados de ácidos grasos y apelina sintética con mayor vida media
|
CN114652817A
(zh)
|
2015-02-09 |
2022-06-24 |
费斯生物制药公司 |
用于治疗肌肉疾病和病症的方法和组合物
|
TWI748945B
(zh)
|
2015-03-13 |
2021-12-11 |
德商賽諾菲阿凡提斯德意志有限公司 |
第2型糖尿病病患治療
|
TW201705975A
(zh)
|
2015-03-18 |
2017-02-16 |
賽諾菲阿凡提斯德意志有限公司 |
第2型糖尿病病患之治療
|
US10336802B2
(en)
|
2015-04-16 |
2019-07-02 |
Zealand Pharma A/S |
Acylated glucagon analogue
|
JOP20190086A1
(ar)
|
2016-10-21 |
2019-04-18 |
Novartis Ag |
مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
|
RU2753193C2
(ru)
|
2016-12-09 |
2021-08-12 |
Зилэнд Фарма А/С |
Ацилированные двойные агонисты glp-1/glp-2
|
AR112480A1
(es)
|
2017-08-24 |
2019-10-30 |
Novo Nordisk As |
Composiciones de glp-1 y sus usos
|
MA53076B1
(fr)
|
2018-02-02 |
2023-11-30 |
Novo Nordisk As |
Compositions solides comportant un agoniste glp-1, du sel d'acide n-(8-(2-hydroxybenzoyl)amino)caprylate et un lubrifiant
|
UY38072A
(es)
|
2018-02-07 |
2019-10-01 |
Novartis Ag |
Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
|
UY38485A
(es)
|
2018-11-27 |
2020-06-30 |
Novartis Ag |
Compuestos tetrámeros cíclicos como inhibidores de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9), método de tratamiento, uso y su preparación
|
WO2020110011A1
(en)
|
2018-11-27 |
2020-06-04 |
Novartis Ag |
Cyclic peptides as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorders
|
EP3887363A1
(en)
|
2018-11-27 |
2021-10-06 |
Novartis AG |
Cyclic pentamer compounds as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorder
|
GB201917723D0
(en)
*
|
2019-12-04 |
2020-01-15 |
Nv Rose Llc |
Stable liquid formulations of glucagon-like peptide 1 or analogues thereof
|
KR20220143037A
(ko)
|
2020-02-18 |
2022-10-24 |
노보 노르디스크 에이/에스 |
Glp-1 조성물 및 이의 용도
|
WO2023084449A1
(en)
|
2021-11-12 |
2023-05-19 |
Novartis Ag |
Diaminocyclopentylpyridine derivatives for the treatment of a disease or disorder
|
AR127698A1
(es)
|
2021-11-23 |
2024-02-21 |
Novartis Ag |
Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno
|